Oral Communications 3: Pituitary and Neuroendocrinology

ea0073oc3.1 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat is an effective and well-tolerated treatment for Cushing’s Disease (CD): Results from a Phase III, multicentre, randomized, double-blind study with an initial placebo-controlled phase (LINC 4)

Gadelha Monica , MarieBex , Feelders Richard , Heaney Anthony , Auchus Laviola , Gilis-Januszewska Laviola , Witek Przemyslaw , Zhanna Belaya , Zhihong Liao , Chen Ku Witek , Carvalho Davide , Roughton Michael , Wojna Judi , Hofstetter Georg , Pedroncelli Alberto , Snyder Peter

IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...

0 shares

ea0073oc3.2 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH–and GH-secreting pituitary neuroendocrine tumor (PitNETs) cell lines

Gesmundo Iacopo , Fanciulli Alessandro , Alvarez Clara V. , Dieguez Carlos , Zatelli Maria Chiara , Grottoli Silvia , Arvat Emanuela , Castaño Justo P. , Cai Renzhi , Sha Wei , Fuentes-Fayos ño , Luque Raùl M. , Ghigo Ezio , Schally Raùl M. , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH). Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are preferre...

0 shares

ea0073oc3.3 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Metyrapone treatment in endogenous Cushing’s syndrome. Long term efficacy and safety results of the extension of the phase III/IV study PROMPT

Nieman Lynnette , Boscaro Marco , Carla Scaroni , Deutschbein Timo , Mezosi Emese , Driessens Natacha , Georgescu Carmen Emanuela , Hubalewska-Dydejczyk Alicja , Berker Dilek , Jarzab Barbara , Maiter Dominique , Reincke Martin , Loli Paola , Zampetti Benedetta , Atmaca Raùl M. , Badiu Corin , Beckers Albert , Bolanowski Marek , Cavagnini Francesco , Unger Nicole , Giordano Roberta , Hanzu Felicia , Terzolo Massimo , Bostnavaron Martine , Tőke Judit , Toth Miklos

BackgroundRetrospective studies led to European approval of the steroidogenesis inhibitor Metyrapone for the treatment of endogenous Cushings syndrome (CS). We prospectively showed good efficacy and safety of Metyrapone after 12 weeks (Wk12) treatment in the phase III/IV PROMPT study and now report results of an extension study (EXT) sponsored by HRA Pharma Rare Diseases.DesignThis was a single arm, ope...

2 shares

ea0073oc3.4 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Truncated somatostatin receptor variant SST5TMD4 determines somatostatin analogs response in corticotropinomas

Alejandro Ibáñez-Costa , Vázquez-Borrego Mari C. , Moreno-Moreno Paloma , Fuentes-Fayos Antonio C. , Moreno Eva Venegas , Fuentes-Fayos Juan Antonio , Herrera-Martínez Aura D. , Gahete Ortiz Manuel , Soto-Moreno Alfonso , Gálvez-Moreno Ángeles María , Luque Raul M. , Castaño Justo P.

IntroductionCushings disease is the result of prolonged exposure to excess cortisol caused by a pituitary tumor, known as corticotropinoma, which hypersecretes adrenocorticotropin (ACTH). Treatment with somatostatin analogs (SSA) has been shown to reduce hormone secretion and, to a lower extent, tumor growth in some subtypes of pituitary tumors, such as growth hormone secreting tumors. However, SSA are commonly ineffective in corticotropinomas. Pre...

0 shares

ea0073oc3.5 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Pregnancies after childhood craniopharyngioma – Results of KRANIOPHARYNGEOM 2000/2007

Sowithayasakul Panjarat , Boekhoff Svenja , Bison Brigitte , Müller Hermann

BackgroundData on female fertility, pregnancy, and outcome of offspring after childhood-onset craniopharyngioma (CP) are rare.Study designObservational study on pregnancy rate and outcome of offspring after CP in postpubertal, female patients recruited in KRANIOPHARYNGEOM 2000/2007 since 2000.Results451 CP patients (223 female) have been recruited. 269 CP patients...

0 shares

ea0073oc3.6 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Expression and possible role of integrins in corticotroph tumours

Chen Xiao , Simon Julia , Luis Perez-Rivas , Jörg Flitsch , Honegger Jürgen , Rachinger Walter , Stalla Günter , Reincke Martin , Theodoropoulou Marily

IntroductionIntegrins are heterodimeric transmembrane proteins composed of alpha and beta subunits that mediate cell-cell and cell-extracellular matrix (ECM) interactions. Several integrins are overexpressed in human cancers and their ECM recognition motif, arginine-glycine-aspartate (RGD), is being utilized for tumour imaging and targeting.AimTo explore the expression and function of RGD-binding integrins in...

0 shares

Endocrine Abstracts

European Congress of Endocrinology 2021